Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Up 117.4% in January

Hoth Therapeutics, Inc. (NASDAQ:HOTH) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 633,400 shares, a growth of 117.4% from the December 31st total of 291,300 shares. Based on an average trading volume of 8,650,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 9.3% of the shares of the company are sold short.

Institutional Investors Weigh In On Hoth Therapeutics

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC acquired a new stake in Hoth Therapeutics, Inc. (NASDAQ:HOTH) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned approximately 0.47% of Hoth Therapeutics at the end of the most recent reporting period. 7.08% of the stock is currently owned by hedge funds and other institutional investors.

Hoth Therapeutics Trading Down 3.9 %

HOTH stock traded down $0.05 during trading hours on Wednesday, hitting $1.24. 375,459 shares of the stock were exchanged, compared to its average volume of 28,532,863. Hoth Therapeutics has a 12 month low of $0.58 and a 12 month high of $3.80. The firm has a market capitalization of $8.56 million, a P/E ratio of -0.94 and a beta of 0.75. The company has a 50-day simple moving average of $1.07 and a two-hundred day simple moving average of $0.92.

Hoth Therapeutics (NASDAQ:HOTH) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01). On average, equities research analysts predict that Hoth Therapeutics will post -1.18 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have commented on HOTH shares. Benchmark reiterated a “speculative buy” rating and issued a $3.00 price objective on shares of Hoth Therapeutics in a report on Friday, October 11th. D. Boral Capital reiterated a “buy” rating and issued a $5.00 price target on shares of Hoth Therapeutics in a research note on Tuesday, January 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Hoth Therapeutics in a report on Thursday, January 23rd.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.